Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.

about

Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.

Item

http://www.wikidata.org/entity/Q47603836

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@en

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@nl

type

Item

label

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@en

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@nl

prefLabel

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@en

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@nl

P1476

Viral-specific T-cell transfer ...... ctions or diseases after HSCT.

@en

P2093

A Campidelli

http://www.w3.org/2001/XMLSchema#string

C Qian

http://www.w3.org/2001/XMLSchema#string

D Bensoussan

http://www.w3.org/2001/XMLSchema#string

L Reppel

http://www.w3.org/2001/XMLSchema#string

M D'aveni

http://www.w3.org/2001/XMLSchema#string

V Decot

http://www.w3.org/2001/XMLSchema#string

Y Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Antiviral T-cell therapy

Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.

Adoptive immunotherapy with antigen-specific T cells during extracorporeal membrane oxygenation (ECMO) for adenovirus-related respiratory failure in a child given haploidentical stem cell transplantation.

T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.

P2888

bmt.2017.232

P31

scholarly article

P356

10.1038/BMT.2017.232

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29058697

http://www.w3.org/2001/XMLSchema#string